𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon α therapy for patients with essential thrombocythemia : Final results of a phase II study initiated in 1986

✍ Scribed by Rashid Saba; Elias Jabbour; Francis Giles; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Emil J. Freireich; Guillermo Garcia-Manero; Hagop Kantarjian; Srdan Verstovsek

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
92 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon-α and chemohormonal therapy f
Interferon-α and chemohormonal therapy for patients with advanced melanoma : Final results of a Phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program
✍ James J. Stark; Robert O. Dillman; Richard Schulof; Michael C. Wiemann; Neil M. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Background: The treatment of metastatic melanoma remains unsatisfactory despite encouraging results with biotherapy and combination chemotherapy. combining these two modalities may improve outcomes for such patients. ## Methods: Patients who were eligible for this study had metastatic melanoma

A Phase II study of “decrescendo” interl
A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy
✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Gemcitabine and oxaliplatin in the treat
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma : Final results of a single-institution Phase II study
✍ Camillo Porta; Matteo Zimatore; Ilaria Imarisio; Anna Natalizi; Andrea Sartore-B 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 3 views

## Abstract ## BACKGROUND Currently, there is no standard treatment for patients with advanced renal cell carcinoma (RCC) who do not experience a response to first‐line immunotherapy. In the current Phase II study, the authors explored the antitumor activity of a combination of gemcitabine and oxa

Interferon-α-2a with or without 13-cis r
Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)
✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin